Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program)
Observational
Observational Model: Case-Only, Time Perspective: Prospective
Incidence of adverse drug reactions and serious adverse events in subjects who received Nexavar
After Nexavar administration, up to 1 year
Yes
Bayer Study Director
Study Director
Bayer
Japan: Ministry of Health, Labor and Welfare
15037
NCT01412671
February 2008
September 2011
Name | Location |
---|